Tsumura & Co.
Regarding the Signing of the Share Acquisition Agreement of Yomeishu Seizo Co., Ltd.
Tsumura & Co. has signed a share acquisition agreement with Yomeishu Seizo Co., Ltd., acquiring the core business of Yomeishu Seizo for approximately 6.8 billion yen. The acquisition will proceed in stages from April to August 2026.
Key Figures
- Transfer Amount: 6.8 billion yen
- Yomeishu Related Business Net Sales: 8,541 million yen
- Yomeishu Related Business Segment Profit: 2,365 million yen
AI要約
Overview of M&A
Tsumura & Co. has signed a share acquisition agreement with Yomeishu Seizo Co., Ltd. The acquisition will be carried out in four phases: tender offer, squeeze-out through share consolidation, company split, and negotiated transfer, scheduled for completion between early April and around August 2026. The acquisition amount is 6.8 billion yen, through which Tsumura will take over Yomeishu Seizo's core business portfolio and focus management resources on synergistic businesses.
Business Strategy and Synergy Effects
Leveraging Yomeishu Seizo's strengths in the widely recognized and trusted Yomeishu medicinal liquor brand, as well as its No.1 market share brand and production technology for medicinal liquors, Tsumura Group aims to expand its domestic healthcare product business domain. The companies will promote expansion of sales channels in drugstores and specialized dispensing pharmacies utilizing both brands' assets, as well as strengthen online sales. This will enhance health support functions in the wellness field and aim for diversification of the new business portfolio.
